Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 9.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 172,582 shares of the medical equipment provider's stock after selling 18,894 shares during the period. Allspring Global Investments Holdings LLC owned 0.25% of Lantheus worth $15,351,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of LNTH. Janus Henderson Group PLC raised its holdings in shares of Lantheus by 7.7% during the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider's stock valued at $393,844,000 after buying an additional 257,022 shares during the period. Geode Capital Management LLC raised its holdings in shares of Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock valued at $184,798,000 after buying an additional 32,551 shares during the period. Reinhart Partners LLC. raised its holdings in shares of Lantheus by 9.9% during the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider's stock valued at $122,280,000 after buying an additional 123,282 shares during the period. Swedbank AB raised its holdings in shares of Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after buying an additional 385,000 shares during the period. Finally, Portolan Capital Management LLC raised its holdings in shares of Lantheus by 6.1% during the 3rd quarter. Portolan Capital Management LLC now owns 670,881 shares of the medical equipment provider's stock valued at $73,629,000 after buying an additional 38,776 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 1.50% of the company's stock.

Analyst Ratings Changes

LNTH has been the topic of several analyst reports. Truist Financial restated a "buy" rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. JMP Securities restated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective on the stock. Finally, StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $131.86.

Lantheus Stock Performance

Shares of NASDAQ LNTH traded down $0.51 during trading on Thursday, reaching $80.88. The stock had a trading volume of 880,328 shares, compared to its average volume of 800,957. Lantheus Holdings, Inc. has a one year low of $56.06 and a one year high of $126.89. The stock has a market cap of $5.62 billion, a PE ratio of 13.46 and a beta of 0.44. The firm's 50 day moving average price is $90.82 and its two-hundred day moving average price is $97.32.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.